Concepedia

Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

Craig C. Hofmeister, Buffy Jansak, Nathan Denlinger, Eric H. Kraut, D.M. Benson, Sherif S. Farag

Leukemia Research · 2007 · 14 citations · 10 references

DOI

Concepts

References

10

World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues

D. K. Hossfeld · Annals of Oncology · 2002 · 4.6K citations · Full text

, , +14

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

, , +12

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Joan Bladé, Diana Samson, Donna Reece et al. · British Journal of Haematology · 1998 · 1.5K citations

, , +17

Malignant Cells Can Be Sensitized to Undergo Growth Inhibition and Apoptosis by Arsenic Trioxide Through Modulation of the Glutathione Redox System

Jie Dai, Rona Singer Weinberg, Samuel Waxman et al. · Blood · 1999 · 531 citations

, , +17

Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells

Jennifer M. Grad, Nizar J. Bahlis, Isildinha Reis et al. · Blood · 2001 · 269 citations · Full text

, , +13